Quick Answer
Neuphoria Therapeutics Inc. reported Stockholders Equity of $19.00 million for fiscal year 2025.
Neuphoria Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $19.00M | +8.6% |
| 2024 | $17.49M | -20.5% |
| 2023 | $22.01M | -43.9% |
| 2022 | $39.23M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $29.70M | +116.0% | +137.4% |
| September 30, 2025 | $12.51M | -26.7% | -34.2% |
| June 30, 2025 | $19.00M | +8.6% | -26.9% |
| March 31, 2025 | $26.00M | +44.9% | +89.1% |
| December 31, 2024 | $13.75M | -29.5% | -19.5% |
| September 30, 2024 | $17.07M | -0.9% | -2.4% |
| June 30, 2024 | $17.49M | -20.5% | -2.5% |
| March 31, 2024 | $17.95M | — | -8.0% |
- Neuphoria Therapeutics Inc. showed an increase of +8.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Neuphoria Therapeutics Inc.’s stockholders equity has declined by 51.6% (from $39.23 million to $19.00 million).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: